Biohaven Ltd. (BHVN) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Biohaven Ltd. is a biopharmaceutical company focused on immunology, obesity, neuroscience, and oncology. The company is currently pre-revenue, advancing a portfolio of therapeutics including Kv7 ion channel modulators (opakalim), MoDE/TRAP degraders (BHV-1300, BHV-1400), and myostatin inhibitors (taldefgrobep alfa). In Q4 2025, the company initiated strategic portfolio optimization to prioritize three key late-stage programs.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(137,311) | $(198,147) | $(267,843) | $(419,824) |
| Net Loss Per Share | $(0.91) | $(1.94) | $(1.80) | $(4.11) |
| R&D Expenses | $100,814 | $184,367 | $204,641 | $371,951 |
| G&A Expenses | $24,085 | $27,334 | $50,686 | $61,311 |
| Cash & Equivalents | $238,033 | $165,797 | $238,033 | $165,797 |
| Marketable Securities | $29,833 | $89,180 | $29,833 | $89,180 |
| Total Liquidity | $267,866 | $254,977 | $267,866 | $254,977 |
| Notes Payable (Fair Value) | $259,480 | $238,900 | $259,480 | $238,900 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by $86.8 million in Q2 2026 compared to Q2 2025, driven by a strategic reprioritization of programs initiated in Q4 2025 and the absence of one-time milestone payments recorded in the prior year (specifically $15.0M for BHV-8000 and $10.0M for BHV-1530).
- Non-Cash Fair Value Losses: Other (expense) income turned negative in Q2 2026 ($12.0M expense) compared to income in Q2 2025 ($13.8M). This shift was primarily due to non-cash losses from changes in the fair value of the Note Purchase Agreement (NPA) liability, offsetting gains from derivative settlements in the prior year.
- Capital Raise: In Q1 2026, the company raised approximately $178.9 million through the issuance of common shares under its Equity Distribution Agreement.
- Debt Liability Increase: The fair value of the Notes Payable increased from $238.9 million to $259.5 million due to changes in fair value inputs, including credit risk and probability of regulatory approval.
Outlook, Risks, and Management Commentary
- Clinical Progress:
- BHV-1300 (Graves' Disease): Initiated a pivotal Phase 3 trial. Phase 1b data showed >80% reduction in pathogenic antibodies and normalization of thyroid hormones.
- BHV-1400 (IgA Nephropathy): Phase 1b data showed rapid lowering of Gd-IgA1. Plans to initiate a pivotal study in H2 2026.
- Opakalim (Epilepsy): Enrollment in the RISE 3 pivotal study is complete; topline results expected in H2 2026. Open-label extension data showed 54-56% responder rates.
- Taldefgrobep Alfa (Obesity): Phase 2 enrollment complete; topline results expected in H2 2026.
- Liquidity: Management expects existing cash and marketable securities ($267.9 million) to fund operations for at least one year. However, the company anticipates needing additional capital to execute its growth strategy.
- Debt Covenants: The Note Purchase Agreement contains a covenant requiring audited financial statements without a "going concern" qualification by March 1, 2027. A breach could trigger an event of default and acceleration of the $250 million principal plus premiums.
- Legal Proceedings:
- Trade Secret Litigation: Won a jury verdict in July 2026 against Avilar Therapeutics, awarded ~$1.0 million to Biohaven. Subject to appeal.
- Shareholder Complaint: A securities class action lawsuit filed in 2025 regarding disclosures on troriluzole and opakalim remains pending; the company filed a motion to dismiss in May 2026.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $235 million operating cash burn (YTD 2026) against the $268 million liquidity position.
- Debt Fair Value Volatility: Monitor the fair value adjustments of the $259.5 million Notes Payable, which significantly impact reported net loss but are non-cash.
- Covenant Compliance: Confirm the status of the "going concern" audit opinion requirement for the 2026 fiscal year to avoid default on the Note Purchase Agreement.
- Clinical Milestones: Track the H2 2026 topline data releases for Opakalim (RISE 3), BHV-1300, BHV-1400, and Taldefgrobep Alfa, as these are critical for future revenue and potential debt repayment triggers.
- Equity Dilution: Assess the remaining capacity under the Equity Distribution Agreement ($350 million available) and the potential for further dilution to fund operations.